We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-30.82%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.7B
AUM Growth
-$1.14B
Cap. Flow
+$29.8M
Cap. Flow %
1.1%
Top 10 Hldgs %
59.73%
Holding
123
New
18
Increased
25
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$86.4M
2
BABA icon
Alibaba
BABA
+$51.3M
3
NIO icon
NIO
NIO
+$28.5M
4
ALLO icon
Allogene Therapeutics
ALLO
+$10.6M
5
ARRY
Array Biopharma Inc
ARRY
+$9.1M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$31.2M
2
ANAB icon
AnaptysBio
ANAB
+$11.2M
3
FOLD
Amicus Therapeutics
FOLD
+$11M
4
ZGNX
Zogenix, Inc.
ZGNX
+$8.19M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.69M

Sector Composition

Rank Sector Weight
1 Healthcare 48.78%
2 Consumer Discretionary 24.57%
3 Real Estate 0.28%
4 Communication Services 0.12%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
101
Dianthus Therapeutics
DNTH
$5.58B
$1.14M 0.04%
12,500
– –
YMAB
102
DELISTED
Y-mAbs Therapeutics
YMAB
$1.02M 0.04%
50,000
-100,000
-67% -$2.3M
TRIL
103
DELISTED
Trillium Therapeutics Inc.
TRIL
$257K 0.01%
150,000
– –
NVLN
104
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$215K 0.01%
256,400
– –
ADVM
105
DELISTED
Adverum Biotechnologies
ADVM
– –
-40,000
Closed -$2.42M
AXDX
106
CALL
DELISTED
Accelerate Diagnostics
AXDX
– –
-50,000
Closed -$11.5M
BABA icon
107
CALL
Alibaba
BABA
$276B
– –
-100,000
Closed -$16.5M
C icon
108
CALL
Citigroup
C
$215B
– –
-250,000
Closed -$17.9M
ELAN icon
109
Elanco Animal Health
ELAN
$12.8B
– –
-100,000
Closed -$3.49M
FLEX icon
110
Flex
FLEX
$37.6B
– –
-331,750
Closed -$3.28M
NTLA icon
111
Intellia Therapeutics
NTLA
$1.5B
– –
-90,000
Closed -$2.58M
NVAX icon
112
Novavax
NVAX
$1.2B
– –
-25,000
Closed -$940K
IMDX
113
Insight Molecular Diagnostics
IMDX
$143M
– –
-7,500
Closed -$375K
SYBX
114
DELISTED
Synlogic
SYBX
– –
-13,333
Closed -$2.84M
UBX
115
DELISTED
Unity Biotechnology
UBX
– –
-5,000
Closed -$815K
XBI icon
116
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.97B
– –
-200,000
Closed -$19.2M
XENE icon
117
Xenon Pharmaceuticals
XENE
$6.16B
– –
-250,000
Closed -$3.3M
ATYR
118
aTyr Pharma
ATYR
$47M
– –
-35,714
Closed -$406K
HSTO
119
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-2,500
Closed -$2.9M
LOGM
120
DELISTED
LogMein, Inc.
LOGM
– –
-65,000
Closed -$5.79M
TSRO
121
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-500,000
Closed -$19.5M
TSRO
122
DELISTED
TESARO, Inc.
TSRO
– –
-800,000
Closed -$31.2M
LJPC
123
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-200,000
Closed -$4.03M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2018 Portfolio in Review

As of Q4 2018, Artal Group held 123 positions worth $2.7B, down 30% from $3.84B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group's Q4 2018 filing shows 18 new, 25 increased, 16 reduced and 19 closed positions. Its largest new stake was Moderna: 5,256,298 shares worth $80.3M. The largest sale was TESARO, Inc., an estimated $31.2M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 46% a quarter earlier, followed by Consumer Discretionary and Real Estate.

  • Artal Group's largest Q4 2018 buy was Moderna: 5,256,298 shares worth $80.3M.
  • Artal Group added most to Alibaba in Q4 2018, an estimated $51.3M increase.
  • Artal Group's biggest Q4 2018 reduction was AnaptysBio, cutting an estimated $11.2M.
  • Artal Group fully exited TESARO, Inc. in Q4 2018, selling an estimated $31.2M.
  • Artal Group's ten largest holdings make up 60% of its $2.7B portfolio in Q4 2018.
  • Artal Group opened 18 new positions and closed 19 in Q4 2018.
  • Artal Group's portfolio value fell 30% quarter-over-quarter to $2.7B.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.